Abstract
Miras AD, le Roux CW. Metabolic surgery versus conventional therapy in type 2 diabetes. Lancet 2021; 397: 256–57—In this Comment, the declaration of interest statement for Carel W le Roux has been corrected to read “CWlR reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards of Novo Nordisk, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Sanofi Aventis, AstraZeneca, Janssen, Bristol-Myers Squibb, Glia, and Boehringer Ingelheim. ClR is a member of the Irish Society for Nutrition and Metabolism outside the area of work commented on here. He is the chief medical officer and director of the Medical Device Division of Keyron since January 2011. Both of these are unremunerated positions. CWlR was a previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. The product has only been tested in rodents and none of Keyron's products are currently licensed. They do not have any contracts with other companies to put their products into clinical practice. No patients have been included in any of Keyron's studies and they are not listed on the stock market. ClR was gifted stock holdings in September 2021 and divested all stock holdings in Keyron in September, 2021. He continues to provide scientific advice to Keyron for no remuneration.” These corrections have been made to the online version as of Feb 3, 2022.
| Original language | English |
|---|---|
| Pages (from-to) | 520-520 |
| Number of pages | 1 |
| Journal | Lancet |
| Volume | 399 |
| Issue number | 10324 |
| Early online date | 5 Feb 2022 |
| DOIs |
|
| Publication status | Published (in print/issue) - 5 Feb 2022 |
Bibliographical note
Funding Information:Miras AD, le Roux CW. Metabolic surgery versus conventional therapy in type 2 diabetes. Lancet 2021; 397: 256–57—In this Comment, the declaration of interest statement for Carel W le Roux has been corrected to read “CWlR reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards of Novo Nordisk, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Sanofi Aventis, AstraZeneca, Janssen, Bristol-Myers Squibb, Glia, and Boehringer Ingelheim. ClR is a member of the Irish Society for Nutrition and Metabolism outside the area of work commented on here. He is the chief medical officer and director of the Medical Device Division of Keyron since January 2011. Both of these are unremunerated positions. CWlR was a previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. The product has only been tested in rodents and none of Keyron's products are currently licensed. They do not have any contracts with other companies to put their products into clinical practice. No patients have been included in any of Keyron's studies and they are not listed on the stock market. ClR was gifted stock holdings in September 2021 and divested all stock holdings in Keyron in September, 2021. He continues to provide scientific advice to Keyron for no remuneration.” These corrections have been made to the online version as of Feb 3, 2022.
Publisher Copyright:
© 2022 Elsevier Ltd
